Maryland Senate Bill 415 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 24-0)
Status: Introduced on January 27 2017 - 25% progression, died in committee
Action: 2017-02-15 - Hearing 2/15 at 1:00 p.m.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Prohibiting a manufacturer or wholesale distributor from engaging in price gouging in the sale of an essential generic drug; requiring the Maryland Medical Assistance Program to notify the manufacturer of an essential generic drug and the Attorney General of a specified increase in the price of the essential generic drug under specified circumstances; requiring a manufacturer of an essential generic drug to submit a specified statement to the Attorney General within 20 days after receipt of a specified notice; etc.

Public Health - Essential Generic Drugs - Price Gouging - Prohibition

Sen. Thomas Miller [D]	Sen. Joan Conway [D]	Sen. John Astle [D]	Sen. Joanne Benson [D]
Sen. Ulysses Currie [D]	Sen. Brian Feldman [D]	Sen. William Ferguson [D]	Sen. Guy Guzzone [D]
Sen. Delores Kelley [D]	Sen. Susan Lee [D]	Sen. Richard Madaleno [D]	Sen. Roger Manno [D]
Sen. Jim Mathias [D]	Sen. Nathaniel McFadden [D]	Sen. Anthony Muse [D]	Sen. Shirley Nathan-Pulliam [D]
Sen. Douglas Peters [D]	Sen. Paul Pinsky [D]	Sen. Victor Ramirez [D]	Sen. Barbara Robinson [D]
Sen. Jim Rosapepe [D]	Sen. William Smith [D]	Sen. Ronald Young [D]	Sen. Craig Zucker [D]

Date	Chamber	Action
2017-02-15	Senate	Hearing 2/15 at 1:00 p.m.
2017-01-27	Senate	First Reading Finance

Type	Source
Summary	https://mgaleg.maryland.gov/mgawebsite/Legislation/Details/SB0415?ys=2017rs
Text	https://mgaleg.maryland.gov/2017RS/bills/sb/sb0415f.pdf
Supplement	https://mgaleg.maryland.gov/2017RS/fnotes/bil_0005/sb0415.pdf